[New concepts in the physiopathology of hypertension. Purinergic receptors].

Rocío Bautista-Pérez, Óscar Pérez-Méndez, Martha Franco
{"title":"[New concepts in the physiopathology of hypertension. Purinergic receptors].","authors":"Rocío Bautista-Pérez, Óscar Pérez-Méndez, Martha Franco","doi":"10.24875/ACM.23000245","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertension is a major risk of morbidity and mortality in patients when it is uncontrolled. In spite of improved therapies currently available for blood pressure control, their complications are far away from being accomplished. Therefore, chronic renal failure is frequently observed in hypertensive patients. Thus, insights on mechanisms that may contribute to arterial pressure control should be studied to prevent life-threatening cardiovascular disorders. Purinergic receptors have been recognized in the physiopathology of hypertension; this review summarizes their participation in the renal abnormalities of the kidney in hypertension. Several studies have suggested the activation of renal purinergic receptors under an elevated interstitial ATP milieu as a fundamental pathway that leads to generation and maintained hypertension. Elevated ATP concentration alters fundamental mechanisms involved in the long-term control of blood pressure such as pressure natriuresis, autoregulation of glomerular filtration rate and renal blood flow, as well as increased tubule-glomerular feedback responses, overall, these alterations decrease sodium excretion; in addition, the expression of ATP receptors is modified. Under a genetical background, ATP induces the production of vasoactive compounds, decreases renal function and induces tubulointerstitial injury before glomerular damage. Simultaneously, a deleterious interaction between angiotensin II and purinergic receptors lead to the progression of renal damage.</p>","PeriodicalId":93885,"journal":{"name":"Archivos de cardiologia de Mexico","volume":" ","pages":"488-494"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de cardiologia de Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/ACM.23000245","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Hypertension is a major risk of morbidity and mortality in patients when it is uncontrolled. In spite of improved therapies currently available for blood pressure control, their complications are far away from being accomplished. Therefore, chronic renal failure is frequently observed in hypertensive patients. Thus, insights on mechanisms that may contribute to arterial pressure control should be studied to prevent life-threatening cardiovascular disorders. Purinergic receptors have been recognized in the physiopathology of hypertension; this review summarizes their participation in the renal abnormalities of the kidney in hypertension. Several studies have suggested the activation of renal purinergic receptors under an elevated interstitial ATP milieu as a fundamental pathway that leads to generation and maintained hypertension. Elevated ATP concentration alters fundamental mechanisms involved in the long-term control of blood pressure such as pressure natriuresis, autoregulation of glomerular filtration rate and renal blood flow, as well as increased tubule-glomerular feedback responses, overall, these alterations decrease sodium excretion; in addition, the expression of ATP receptors is modified. Under a genetical background, ATP induces the production of vasoactive compounds, decreases renal function and induces tubulointerstitial injury before glomerular damage. Simultaneously, a deleterious interaction between angiotensin II and purinergic receptors lead to the progression of renal damage.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[高血压生理病理学的新概念:嘌呤能受体]。
高血压如果得不到控制,是导致患者发病和死亡的主要风险。尽管目前控制血压的疗法有所改进,但其并发症却远未解决。因此,高血压患者经常会出现慢性肾功能衰竭。因此,应深入研究有助于控制动脉压的机制,以防止危及生命的心血管疾病。嘌呤能受体在高血压的生理病理学中已得到认可;本综述总结了它们在高血压肾脏异常中的参与情况。多项研究表明,肾脏嘌呤能受体在间质 ATP 环境升高的情况下被激活,是导致高血压产生和维持的基本途径。ATP 浓度升高会改变长期控制血压的基本机制,如压力利尿、肾小球滤过率和肾血流量的自动调节以及肾小管-肾小球反馈反应的增加,总体而言,这些改变会减少钠的排泄;此外,ATP 受体的表达也会发生改变。在这种基因背景下,ATP 会诱导血管活性化合物的产生,降低肾功能,并在肾小球损伤之前诱导肾小管间质损伤。与此同时,血管紧张素 II 和嘌呤能受体之间的有害相互作用导致肾损伤的恶化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Analysis of COVID-19 patients hospitalized in general wards and intensive care units: Insights from the RIMAC cardiopulmonary imaging registry across Latin American centers. Comment on the firsts insights of the arterial hypertension study in México (RIHTA): are we doing things right? Instituto y no hospital. La distintiva organización que Ignacio Chávez concibió para combatir integralmente a las enfermedades del corazón en México. En el octogésimo aniversario del Instituto Nacional de Cardiología. [Right ventricle-dependent coronary circulation in pulmonary atresia with intact ventricular septum. About three patients without coronary ostium atresia. Is a transient percutaneous decompression maneuver necessary?] [Clinical characterization of patients with complete fetal atrioventricular block].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1